Shopping Cart
Remove All
Your shopping cart is currently empty
Abituzumab
😃Good
Catalog No. T76736Cas No. 1105038-73-0
Alias EMD525797, EMD 525797, DI17E6, DI 17E6
Abituzumab (DI17E6) is a humanized monoclonal antibody targeting Integrin alphaV, with potential anti-cancer activity. It inhibits phosphorylation of FAK, Akt, and ERK and is used in prostate cancer research.
Abituzumab
Abituzumab
😃Good
Catalog No. T76736Alias EMD525797, EMD 525797, DI17E6, DI 17E6Cas No. 1105038-73-0
Abituzumab (DI17E6) is a humanized monoclonal antibody targeting Integrin alphaV, with potential anti-cancer activity. It inhibits phosphorylation of FAK, Akt, and ERK and is used in prostate cancer research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $197 | In Stock | In Stock | |
| 5 mg | $476 | In Stock | In Stock | |
| 10 mg | $787 | - | In Stock | |
| 25 mg | $1,170 | - | In Stock | |
| 50 mg | $1,580 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:98.44% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Abituzumab (DI17E6) is a humanized monoclonal antibody targeting Integrin alphaV, with potential anti-cancer activity. It inhibits phosphorylation of FAK, Akt, and ERK and is used in prostate cancer research. |
| In vitro | Methods: Prostate cancer cell lines were inoculated into 24-well plates and treated with Abituzumab (0.01, 0.1,1,10, 30,100μg/ml). The wound space was measured every 6 hours to observe the invasion and movement of cells. Results: Abituzumab inhibited the movement and invasion of PCa cells. Methods: Prostate cancer cell lines were treated with Abituzumab (100μg/ml) and incubated for 24h. Results: Abituzumab inhibited αV integrin expression and phosphorylation of FAK, Akt and ERK in LNCaP and C4-2B cells. [1] |
| Synonyms | EMD525797, EMD 525797, DI17E6, DI 17E6 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | Integrin aV/ITGAV/CD51 |
| Molecular Weight | 144.58 kDa |
| Cas No. | 1105038-73-0 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Human IgG2 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Abituzumab | purchase Abituzumab | Abituzumab cost | order Abituzumab | Abituzumab in vitro | Abituzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.